Dako and Cell Signaling Technology partner in companion diagnostics
Antibody provider Cell Signaling Technology (CST) has entered into a strategic partnership to supply antibodies for use in Dako companion diagnostics products. Dako, an Agilent Technologies company, is a worldwide provider of cancer diagnostics.
Dako has a record of successful long-term partnerships with companies such as Pfizer, AstraZeneca, Bristol-Myers Squibb, Merck & Co, Amgen and Eli Lilly. Jacob Thaysen, president of Agilent’s Diagnostics and Genomics Group, said the company is now “pleased to work with CST in the development of high-quality, cutting-edge companion diagnostic products that will be an important tool in the diagnosis and treatment of cancer”.
The market for companion diagnostics is steadily growing, as personalised medicine may improve patient care and assist in managing healthcare costs by targeting treatments to individuals more likely to benefit from specific therapies. According to CST CEO Michael J Comb, “Companion diagnostic products have great potential to improve the way we diagnose and treat patients with cancer.
“We believe this partnership will allow our products to contribute to the advancement of personalised medicine,” Comb added.
Nanofibre uniform protects soldiers against chemical threats
A next-generation uniform prototype employs nanofibres to safeguard wearers from chemical and...
Monoclonal antibody shows protection against COVID variants
A monoclonal antibody appears effective at neutralising the numerous variants of SARS-CoV-2, as...
New catalyst enhances efficiency of ammonia conversion
The catalyst has the ability to enhance the efficiency of ammonia conversion, which could improve...
